---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-292551"
form_type: "8-K"
ticker: "ORIC"
cik: "0001796280"
company_name: "Oric Pharmaceuticals, Inc."
filed_at: "2023-12-11T23:59:59+00:00"
generated_at: "2026-06-07T15:00:38.449701+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ORIC-533 Phase 1 shows clinical activity in multiple myeloma; company to seek partner, extends cash runway to 2026

## Summary
- As of Nov 28, 2023, 23 patients dosed (400-2400 mg QD); 100% triple-class refractory, 91% penta-refractory.
- No DLTs, dose reductions, or serious TRAEs; only Grade 1-2 TRAEs observed.
- Confirmed minor response in a penta-refractory patient who had progressed on anti-BCMA bispecific.
- Dose-dependent immune activation (CD8+ T cells, NK cells) at ≥1200 mg; soluble BCMA reductions at 1600 mg.
- Company to complete ORIC-533 dose escalation in Q1 2024 then seek partner; focus on ORIC-114 and ORIC-944.

## SEC filing metadata
- accession: 0001193125-23-292551
- form_type: 8-K
- ticker: ORIC
- cik: 0001796280
- company_name: Oric Pharmaceuticals, Inc.
- filed_at: 2023-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1796280/000119312523292551/0001193125-23-292551-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1796280/000119312523292551/d629143d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-292551
- JSON: https://secwatch.observer/filing/0001193125-23-292551.json
- Plain text: https://secwatch.observer/filing/0001193125-23-292551.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.